Health
Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection – News-Medical.Net
Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19.
Enzyme linked immunosorbent assays (“ELISAs”) are very common research tools used to detect and quantify a target of interest in a wide range of samples. Using the same Affimer reagents that are incorporated into its rapid coronavirus saliva test…
-
Noosa News23 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News23 hours agoE-biker charged with riding dangerously, assaulting cop
-
Business17 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
General22 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands